August 6, 2020
Takara Bio said on August 4 that it will terminate a license deal with China’s Talsy Biopharmaceuticals for its oncolytic viral immunotherapy C-REV (canerpaturev) in China. The Chinese rights for the agent will be returned to the Japanese company. In...read more